Synlogic Inc (NASDAQ:SYBX) — Market Cap & Net Worth
Market Cap & Net Worth: Synlogic Inc (SYBX)
Synlogic Inc (NASDAQ:SYBX) has a market capitalization of $7.08 Million ($7.08 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #27660 globally and #5469 in its home market, demonstrating a -3.55% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Synlogic Inc's stock price $0.61 by its total outstanding shares 11698919 (11.70 Million). Analyse how efficiently does Synlogic Inc generate cash to see how efficiently the company converts income to cash.
Synlogic Inc Market Cap History: 2015 to 2026
Synlogic Inc's market capitalization history from 2015 to 2026. Data shows change from $7.68 Billion to $7.08 Million (-48.23% CAGR).
Index Memberships
Synlogic Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #810 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2615 of 3165 |
Weight: Synlogic Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Synlogic Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Synlogic Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2047.31x
Synlogic Inc's market cap is 2047.31 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $2.21 Billion | $444.00K | -$26.27 Million | 4979.94x | N/A |
| 2017 | $1.70 Billion | $2.44 Million | -$40.38 Million | 696.48x | N/A |
| 2018 | $1.23 Billion | $2.52 Million | -$48.44 Million | 488.15x | N/A |
| 2019 | $452.75 Million | $2.22 Million | -$48.67 Million | 203.57x | N/A |
| 2020 | $379.04 Million | $545.00K | -$56.54 Million | 695.50x | N/A |
| 2021 | $424.67 Million | $1.75 Million | -$58.12 Million | 242.12x | N/A |
| 2022 | $133.37 Million | $1.18 Million | -$66.15 Million | 113.02x | N/A |
| 2023 | $45.04 Million | $3.37 Million | -$57.28 Million | 13.36x | N/A |
| 2024 | $16.38 Million | $8.00K | -$23.36 Million | 2047.31x | N/A |
Competitor Companies of SYBX by Market Capitalization
Companies near Synlogic Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Synlogic Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Synlogic Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Synlogic Inc's market cap moved from $7.68 Billion to $ 7.08 Million, with a yearly change of -48.23%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $7.08 Million | -45.98% |
| 2025 | $13.10 Million | -20.00% |
| 2024 | $16.38 Million | -63.64% |
| 2023 | $45.04 Million | -66.23% |
| 2022 | $133.37 Million | -68.60% |
| 2021 | $424.67 Million | +12.04% |
| 2020 | $379.04 Million | -16.28% |
| 2019 | $452.75 Million | -63.20% |
| 2018 | $1.23 Billion | -27.73% |
| 2017 | $1.70 Billion | -23.02% |
| 2016 | $2.21 Billion | -71.20% |
| 2015 | $7.68 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Synlogic Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $7.08 Million USD |
| MoneyControl | $7.08 Million USD |
| MarketWatch | $7.08 Million USD |
| marketcap.company | $7.08 Million USD |
| Reuters | $7.08 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Synlogic Inc
Synlogic, Inc., a biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618 for the treatment of phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-system… Read more